Filed with ASX · · 2 pages · English
Aroa Biosurgery Ltd reports that the US Centers for Medicare & Medicaid Services has confirmed the outpatient reimbursement rate for its products will remain unchanged in the upcoming year. This announcement highlights Aroa's focus on expanding its market presence in outpatient settings, supported by clinical evidence and responsible pricing. The filing emphasizes the importance of reimbursement stability for healthcare providers and hospitals as Aroa pursues growth opportunities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 9 November 2026 U S C M S C O N F I R M S O U T P A T I E N T R E I M B U R S E M E N T R A T E S F O R 2 0 2 7 Highlights • US CMS confirms the existing payment rate of US$127.14 per square centimetre of wound area treated in outpatient settings for AROA ECM™ sheet products...
Follow Aroa Biosurgery into a list and get an email when it puts out news.
Follow Aroa Biosurgery